Difference between revisions of "Profiles"
Jump to navigation
Jump to search
(Removed Stage 2 CTA Profile, because Stage 3 is being added.) |
|||
| (38 intermediate revisions by 3 users not shown) | |||
| Line 6: | Line 6: | ||
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles=== | ||
| − | *[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening | + | *[[Media:Atherosclerosis Biomarkers Profile 2023Mar28.pdf|CT Atherosclerosis Biomarkers 2023-03-28]] |
| + | *[[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2023.12.19.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19]] | ||
*[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists | *[[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease 2022-07-21]] - Streamlined Profile including Conformance Checklists | ||
| Line 16: | Line 17: | ||
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]] | *[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf|PET Amyloid 2022-06-03]] | ||
| + | *[[Media:QIBA FDG-PET Profile v114.pdf|PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist]] | ||
*[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]] | *[[Media:QIBA FDG-PET Profile v113.pdf|PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18]] | ||
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | ::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | ||
| + | |||
| + | *[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf | US Shear Wave Speed for Liver Fibrosis 2024-01-15]] | ||
| + | ::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]] | ||
| + | ::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]] | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| Line 24: | Line 30: | ||
::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]] | ::*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Protocols - Appendix E:CT Lung Density 2019-06-26]] | ||
| − | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification 2012-08-08]] | + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification (V.1) 2012-08-08]] |
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] | *[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility 2020-10-22]] | ||
| Line 37: | Line 43: | ||
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
| − | *[[Media:QIBA US | + | *[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf | US Volume Blood Flow Profile, Consensus version 2024-01-05]] |
| − | |||
| − | + | *[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | |
| − | + | *[[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06]] | |
| − | |||
| − | *[[Media:QIBA DCE- | ||
| + | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | ||
| Line 54: | Line 58: | ||
* {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]''' | * {Public Comment Resolution} - '''Editor''' collates all comments into a '''resolution spreadsheet''' (see '''[https://docs.google.com/spreadsheets/d/1o3_ssHHIABGKNesUJ_-jL5RYqSx9Eq4o6C2dlIsHQo4/edit?usp=sharing Google Sheet template)]''' | ||
* {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' | * {Site responses for Stage 3} - '''Field Test Leader''' collates all Feedback comments into a '''[https://docs.google.com/spreadsheets/d/1JW-_iJ7vTJvCf1-y4wsxZ_coO8Po2zWqMNDNrBVyUXM/edit?usp=sharing Feedback Resolution spreadsheet]''' | ||
| + | ''' | ||
| + | |||
| + | '''[[Media:QIBA Profiles and Clinical Applications-v01Nov2023-2.xlsx|QIBA Profiles and Clinical Applications]]''' | ||
| + | |||
====Format for Citing Profiles==== | ====Format for Citing Profiles==== | ||
Cite QIBA Profile documents as: | Cite QIBA Profile documents as: | ||
Revision as of 17:36, 17 January 2024
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- CT Atherosclerosis Biomarkers 2023-03-28
- CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19
- CT Tumor Volume Change for Advanced Disease 2022-07-21 - Streamlined Profile including Conformance Checklists
- PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist
- PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)